I don't think they are terrible(there are respondents and disease is stabilized well). There is good evidence in patients who showed anti tumor activity and no dose limitations/safety issues. However trail being limited to one center and there is still room for better selection of patients(the group is very heterogeneous) and they were heavily pre-treated and proper randomization is lacking. I believe with more centers and better clinical trail design and measurement, it will probably have more promising results.
The reason I am buying huge shares of IMU is the the diversity of pipeline and amazing researchers. More over I like the B cell concept to be innovative.
Ohio State University B-Vaxx Report, page-29
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2275218 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 196677 | 3 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
